Investigational Drug Information for Volitinib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Volitinib?
Volitinib is an investigational drug.
There have been 38 clinical trials for Volitinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 8th 2021.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, and Carcinoma, Renal Cell. The leading clinical trial sponsors are AstraZeneca, Hutchison Medipharma Limited, and Parexel.
There are seventeen US patents protecting this investigational drug and three hundred and twenty-nine international patents.
Summary for Volitinib
| US Patents | 17 |
| International Patents | 329 |
| US Patent Applications | 138 |
| WIPO Patent Applications | 138 |
| Japanese Patent Applications | 18 |
| Clinical Trial Progress | Phase 2 (2021-10-08) |
| Vendors | 38 |
Recent Clinical Trials for Volitinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects | Parexel | Phase 1 |
| A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects | AstraZeneca | Phase 1 |
| Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) | Jeeyun Lee | Phase 2 |
Clinical Trial Summary for Volitinib
Top disease conditions for Volitinib
Top clinical trial sponsors for Volitinib
US Patents for Volitinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Volitinib | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Volitinib | See Plans and Pricing | Compounds and methods for inhibiting JAK | Dizal (Jiangsu) Pharmaceutical Co., Ltd. (Wuxi, Jiangsu Province, CN) | See Plans and Pricing |
| Volitinib | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Volitinib | See Plans and Pricing | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | See Plans and Pricing |
| Volitinib | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Volitinib | See Plans and Pricing | Crystalline forms | Array Biopharma Inc. (Boulder, CO) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Volitinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Volitinib | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| Volitinib | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| Volitinib | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| Volitinib | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
| Volitinib | European Patent Office | EP3981392 | 2036-05-05 | See Plans and Pricing |
| Volitinib | Hong Kong | HK1249728 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
